Genetic alterations in tumors, as predictor of response to targeted-therapies or as prognostic
markers, are clinically relevant to determine adequate therapeutic management. Tumor
biopsy is currently the golden standard for somatic alterations assessment, but this approach
is invasive and does not consider tumor heterogeneity. In various body fluids like plasma,
somatic mutations have been identified. Circulating tumor DNA (ctDNA) holds promises in
tumor burden monitoring or malignancies early detection. Since allele frequencies of …